For example, RET rearrangement was not considered as level A in thyroid cancer until December 1, 2020, when the FDA approved pralsetinib for the treatment of adult and pediatric patients (12 years of age and older) with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory. This evidence concerns the gene RET and thyroid gland carcinoma.